THANK YOU FOR SUBSCRIBING
Getting therapeutic molecules across the blood-brain barrier remains a persistent constraint in central nervous system drug development. The 8th CNS Drug Delivery Summit, scheduled for December 1-3, 2026 in Boston, will examine technologies intended to improve brain exposure while addressing the scientific and development hurdles that remain.
Clinical progress in blood-brain barrier shuttle technology has given researchers new evidence to evaluate. Denali’s Avlayah has received FDA approval using BBB shuttle technology, while Roche’s Trontinemab program is providing additional clinical insights into receptor-mediated transport. These developments are directing attention toward how biologics can reach the CNS and how similar delivery mechanisms might support broader therapeutic programs.
The summit will bring together more than 100 senior leaders from biopharma and academia. Its program covers brain shuttle technologies alongside oligonucleotide delivery, with discussions extending to focused ultrasound and gene therapy approaches. Participants include experts from Roche and Novartis, along with representatives from Eli Lilly and AbbVie.
Translating promising delivery mechanisms into viable therapies still involves difficult decisions. Developers need evidence that increased CNS exposure can be reproduced clinically while controlling toxicity and achieving suitable biodistribution. The agenda addresses these questions through sessions on imaging and translational models, giving development teams opportunities to examine how brain penetration and target engagement can be measured.
Technology development is also moving beyond established transferrin receptor approaches. Sessions will examine emerging blood-brain barrier targets and new shuttle architectures designed to improve tissue penetration. Investment considerations form another part of the program, including the evidence needed to move delivery platforms from research into clinical development and potential partnerships.
Healthcare Tech Outlook is serving as a media partner because CNS delivery technology sits at the intersection of medical innovation and technology-enabled healthcare advancement covered by the publication. Its readership includes healthcare executives and technology decision-makers evaluating developments that can influence patient care. Editorial coverage can extend relevant discussions beyond Boston by examining how delivery technologies progress toward practical therapeutic applications.
The next phase of CNS delivery will depend on more than demonstrating that therapeutic agents can cross the blood-brain barrier. Evidence around distribution, safety and clinical translation will determine which technologies can progress into viable treatment platforms, making the findings discussed in Boston relevant to the wider development of CNS therapeutics.
More in News